Plinabulin

Phase 3Small molecule

BBeyondSpring Pharmaceuticals Inc.

Plinabulin is one of 52 small molecule programs targeting Multiple Myeloma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple MyelomaActive, not recruiting

Non-Squamous NSCLCNot yet recruiting

Multiple MyelomaPhase 2

Active, not recruiting

Non-Squamous NSCLCPhase 3

Not yet recruiting

Competition

Competitive Landscape

282 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Empliciti

Bristol-Myers Squibb

Phase 3

45 2

Keytruda

Merck & Co.

Phase 3

17 3

Venclexta

AbbVie

Phase 3

17 4

Biaxin

AbbVie

Phase 3

15 5

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

29 6

Vepesid

AAvyxa

Phase 3

17 7

Cytosar

Teva

Phase 3

4 8

Mozobil

GGenzyme, a Sanofi Company

Phase 3

15 9

BLENREP

GGlaxo Dba Glaxosmithkline

Phase 3

10 10

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Multiple Myeloma

NCT05130827

Q4 2029

Phase 3Not yet recruiting

Non-Squamous NSCLC

NCT07361484

Clinical

Trials by Indication[1]

Neutropenia2 trials

Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia

Unknown status·BBeyondSpring Pharmaceuticals Inc.·Phase 3·NCT03294577·221 enrolled

Plinabulin iv Solution in Prevention of TAC Induced Neutropenia

Completed·BBeyondSpring Pharmaceuticals Inc.·Phase 2·NCT04227990·115 enrolled

Patients With Solid Tumors2 trials

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3

Completed·BBeyondSpring Pharmaceuticals Inc.·Phase 3·NCT03102606·105 enrolled

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2

Completed·BBeyondSpring Pharmaceuticals Inc.·Phase 2·NCT04345900·55 enrolled

Non-Small Cell Lung Cancer1 trial

Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer

Terminated·UUniversity of Washington·Phase 1/2·NCT02846792·5 enrolled

Multiple Myeloma1 trial

Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05130827·17 enrolled

Non-squamous NSCLC1 trial

Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)

Not yet recruiting·BBeyondSpring Pharmaceuticals Inc.·Phase 3·NCT07361484·442 enrolled

2 more indications

Advanced Cancers1 trial

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT04902040·19 enrolled

Small Cell Lung Cancer1 trial

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer

Completed·SSalma Sabbour·Phase 1/2·NCT03575793·39 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Plinabulin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Plinabulin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Plinabulin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BeyondSpring Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBeyondSpring Pharmaceuticals Inc.

Plinabulin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2029

Trials by Indication[1]

Neutropenia2 trials

Patients With Solid Tumors2 trials

Non-Small Cell Lung Cancer1 trial

Multiple Myeloma1 trial

Non-squamous NSCLC1 trial

Advanced Cancers1 trial

Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News